Relypsa Receives Average Rating of “Buy” from Analysts (NASDAQ:RLYP)
Relypsa (NASDAQ:RLYP) has received a consensus rating of “Buy” from the eight analysts that are presently covering the stock, American Banking News reports. Eight analysts have rated the stock with a buy recommendation, The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $48.50.
In other Relypsa news, Director Klaus R. Dr Veitinger sold 4,167 shares of the stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $27.73, for a total transaction of $115,550.91. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Separately, analysts at Stifel Nicolaus raised their price target on shares of Relypsa from $45.00 to $47.00 in a research note on Tuesday. They now have a “buy” rating on the stock.
Relypsa (NASDAQ:RLYP) traded up 2.65% on Wednesday, hitting $25.55. 47,428 shares of the company’s stock traded hands. Relypsa has a one year low of $11.55 and a one year high of $52.74. The stock’s 50-day moving average is $24.01 and its 200-day moving average is $28.52. The company’s market cap is $868.6 million.
Relypsa (NASDAQ:RLYP) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.51) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.57) by $0.06. On average, analysts predict that Relypsa will post $-2.55 earnings per share for the current fiscal year.
Relypsa, Inc is a pharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.